There are currently no generic versions of Anoro Ellipta available in the United States [1]. Anoro Ellipta is a combination inhaler containing umeclidinium and vilanterol, used to treat chronic obstructive pulmonary disease (COPD) [2].
When Does Anoro Ellipta Patent Protection Expire?
The patent expiration timeline for Anoro Ellipta is complex due to multiple patents covering its composition, method of use, and manufacturing. Information regarding specific patent expiry dates is available through resources that track pharmaceutical patents, such as DrugPatentWatch.com [3]. The eventual expiration of these patents could pave the way for generic manufacturers to seek approval for their own versions of the drug.
What Happens When Generic Anoro Ellipta Becomes Available?
When generic versions of Anoro Ellipta become available, they will offer a lower-cost alternative for patients and healthcare systems [4]. The availability of generics typically leads to a significant decrease in drug prices. Generic drugs are required to meet the same standards for quality, safety, and efficacy as their brand-name counterparts before they can be approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) [5].
How Do Generic Anoro Ellipta Prices Compare?
Generic drug prices are generally substantially lower than those of the branded drug. While specific pricing for a generic Anoro Ellipta is not yet established, historical trends show that generic alternatives can reduce costs by 80-85% or more compared to the brand-name drug [4].
Can Biosimilars Enter the Market for Anoro Ellipta?
Anoro Ellipta is a small-molecule drug, not a biologic. Therefore, the pathway for market entry for generic versions is through Abbreviated New Drug Applications (ANDAs), not through the biosimilar pathway which applies to biologic drugs [5]. Biosimilars are highly similar versions of complex biologic medicines, whereas generics are identical or nearly identical to small-molecule drugs.
Who Makes Generic Anoro Ellipta?
Currently, no company manufactures generic Anoro Ellipta as it is not yet available on the market. Once patent protections expire and regulatory approvals are granted, various pharmaceutical companies specializing in generic drug production may seek to market their versions of Anoro Ellipta [1].
What are the Active Ingredients in Anoro Ellipta?
Anoro Ellipta contains two active ingredients: umeclidinium, which is a long-acting muscarinic antagonist (LAMA), and vilanterol, which is a long-acting beta2-adrenergic agonist (LABA) [2]. Both work together to relax the airways and make breathing easier for individuals with COPD.
What Side Effects Should Patients Be Aware Of?
Common side effects associated with Anoro Ellipta include nasopharyngitis (common cold symptoms), hypertension, back pain, chest pain, and diarrhea [2]. Patients should consult with their healthcare provider regarding any potential side effects or concerns.
How Does Anoro Ellipta Compare to Other COPD Medications?
Anoro Ellipta is a combination inhaler that provides long-term maintenance treatment for COPD. Other COPD medications include single-ingredient inhalers (e.g., only a LAMA or only a LABA), other dual-combination inhalers (e.g., LAMA/LABA, LABA/ICS), and rescue inhalers (short-acting bronchodilators) [6]. The choice of medication depends on the severity of COPD, individual patient response, and physician recommendation.
---
Sources:
1. DrugPatentWatch.com. (n.d.). Anoro Ellipta. Retrieved from https://drugpatentwatch.com/drugs/anoro-ellipta
2. U.S. Food & Drug Administration. (n.d.). Anoro Ellipta. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205042s000lbl.pdf
3. DrugPatentWatch.com. (n.d.). Anoro Ellipta Patent Expiration. Retrieved from https://drugpatentwatch.com/drugs/anoro-ellipta/patent-expiration
4. U.S. Food & Drug Administration. (2020, August 21). Generic Drugs: What They Are and How They Work. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-what-they-are-and-how-they-work
5. U.S. Food & Drug Administration. (2022, October 12). Generic Drug Approvals and Patents. Retrieved from https://www.fda.gov/drugs/patent-certification-and-fec/generic-drug-approvals-and-patents
6. National Heart, Lung, and Blood Institute. (n.d.). COPD Medicines. Retrieved from https://www.nhlbi.nih.gov/health-topics/copd-medicines